Abstract
Multidrug resistance (MDR) is a major problem in lung cancer. Tc-99m methoxyisobutyl isonitrile (MIBI) has been demonstrated to be a non-invasive marker to diagnose MDR1 related P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) expression in various solid tumors. The aim of this study was to evaluate the relationship between the degree of Tc-99m MIBI uptake and its retention on delayed images and the response to chemotherapy in lung cancer. Twenty-three patients (1 woman and 22 men, age range 40–67 years) with lung cancer (9 small cell and 14 non-small cell) were examined with Tc-99m MIBI imaging before chemotherapy. After i.v. administration of 740 MBq Tc-99m MIBI, planar and SPECT imaging at 30 minutes and 2 hours was performed. Tumor to normal lung uptake ratio (T/N) and percent retention were measured. Response to chemotherapy was evaluated according to follow-up CT and grouped as complete responders (CR), partial responders (PR) and non-responders (NR). Clinical follow-up and CT evaluation revealed that 12 patients had partial remission, 4 patients had complete remission and 7 patients had no-remission after chemotherapy. Statistically, there was no significant correlation between early (30 min), delayed (2 hr) T/N ratios and percent retention of Tc-99m MIBI with chemotherapeutic response of the lung cancer among the three groups (p>0.05). Results of the current study imply that Tc-99m MIBI uptake and the retention index may not correlate with chemotherapy response in lung cancer, so that the accuracy of this method needs to be verified in a larger series with additional investigation at the molecular level.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Burak Z, Argon M, Memiş A, et al. Evaluation of palpable breast masses with99mTc-MIBI: a comparative study with mammography and ultrasonography.Nucl Med Commun 1994; 15: 604–612.
Caner B, Kitapçi M, Ünlü M, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP.J Nucl Med 1992; 33: 319–324.
Yen T, Lin H, Lee C, et al. The role of technetium-99m sestamibi whole-body scans in diagnosing metastatic Hürthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole-body scans.Eur J Nucl Med 1994; 21: 980–983.
Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs.Clin Nucl Med 1989; 14: 333–340.
Chiti A, Maffioli LS, Infante M, et al. Assessment of mediastinal involvement in lung cancer with Technetium-99m-sestamibi SPECT.J Nucl Med 1996; 37: 938–942.
Aktolun C, Bayhan H, Kir M. Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors.Clin Nucl Med 1992; 17: 171–176.
Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organo-technetium complex.Cancer Res 1993; 53: 977–984.
Kostakoĝlu L, Kiratli P, Ruacan Ş, et al. Association of tumor washout rates and accumulation of Technetium-99m-MIBI with expression of p-glycoprotein in lung cancer.J Nucl Med 1998; 39: 228–234.
Ceriani L, Gioveanella L, Bandera M, et al. Semi-quantitative assessment of99Tcm-sestamibi uptake in lung cancer: Relationship with clinical response to chemotherapy.Nucl Med Commun 1997; 18: 1087–1097.
Koukourakis MI, Koukouraki S, Giatromanolaki A, et al. Non-small cell lung cancer functional imaging: increased hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cyiotoxic treatment.Clin Cancer Res 1997; 3: 749–754.
Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxy isobutyl isonitrile) Tc-99m cultured mouse fibroblast.J Nucl Med 1990; 31: 1646–1653.
Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutylisonitrile) technetium (I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential difference.Circulation 1990; 82: 1826–1838.
Moretti JL, Duran Cordobes M, Starzec A, et al. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.J Nucl Med 1998; 39: 1214–1218.
Kaye SB. Clinical drug resistance: the role of factors other than p-glycoprotein.Am J Med 1995; 29: 408–445.
Scagliotti GV, Novello S, Selvaggi G, Multidrug resistance in non-small-cell lung cancer.Ann Oncol 1999; 10 (Suppl 5): 83–86.
Sasaki M, Kuwahara Y, Ichiya Y, et al. Prediction of the chemosensitivity of lung cancer by99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT.J Nucl Med 1999; 40: 1778–1783.
Sasaki M, Kuwabara Y, Yoshida T, et al. Can99mTc MIBI SPECT predict the treatment response of lung cancer?.J Nucl Med 2000; 41 (Suppl 5): 286.
Ikeda K, Oka M, Narasaki F, et al. Lung resistance-related protein gene expression and drug sensitivity in human gastric and lung cancer cells.Anticancer Res 1998; 18: 3077–3080.
Scagliotti GV, Micheistte F, Kalikatzaros G, et al. Betection of multidrug resistance associated P-170 glycoprotein in previously untreated non small cell lung cancer.Anticancer Res 1991; 11: 2207–2210.
Hoffman PC, Mauer AM, Vokes EE. Lung cancer.The Lancet 2000; 355: 479–485.
Canitrot Y, Bichat F, Cole SP, et al. Multidrug resistance genes (MRP) and MDR1 expression in small cell lung cancer xenografts: relationship with response to chemotherapy.Cancer Lett 1998; 130: 133–141.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dirlik, A., Burak, Z., Goksel, T. et al. The role of Tc-99m sestamibi imaging in predicting clinical response to chemotherapy in lung cancer. Ann Nucl Med 16, 103–108 (2002). https://doi.org/10.1007/BF02993712
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02993712